Literature DB >> 8086548

Pseudomonas aeruginosa bacteremia in patients with AIDS.

M H Mendelson1, A Gurtman, S Szabo, E Neibart, B R Meyers, M Policar, T W Cheung, D Lillienfeld, G Hammer, S Reddy.   

Abstract

Twenty-seven episodes of Pseudomonas aeruginosa bacteremia in 21 patients with AIDS were evaluated at the Mount Sinai Medical Center in 1987-1992. Of 21 primary episodes, 12 were acquired in the community, 8 were nosocomial, and one was acquired in a nursing home. Sources of bacteremia (i.e., sites of infection; n = 30) included the lungs (12 cases) an indwelling vascular catheter (9), and the upper respiratory tract (5, including 2 cases of sinusitis, 2 cases of malignant external otitis, and 1 case of epiglottis/pharyngeal cellulitis); in 4 cases the source was unknown. White blood cell counts ranged from 0.1 to 26.2 (mean, 4.32) x 10(3)/mm3; in 19 of 26 cases, the absolute neutrophil count was > 1 x 10(3)/mm3. With the exclusion of primary episodes of bacteremia that resulted in death, the rate of relapse was 33.3% (5 of 15 cases). Mortality for the 25 evaluable episodes of bacteremia was 40% (32% for primary infection and 80% for relapse; P = .06); 52.6% of evaluable patients (10 of 19) ultimately died of P. aeruginosa bacteremia. The institution of appropriate therapy at presentation did not positively affect outcome. Rates of response were higher among episodes treated with a drug combination (an antipseudomonal beta-lactam or monobactam antibiotic plus an aminoglycoside) than among those treated with a single agent (P = .036).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8086548     DOI: 10.1093/clinids/18.6.886

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  30 in total

1.  Pseudomonas aeruginosa exoenzyme S is a biglutamic acid ADP-ribosyltransferase.

Authors:  J Radke; K J Pederson; J T Barbieri
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

Review 2.  Bacterial quorum sensing in pathogenic relationships.

Authors:  T R de Kievit; B H Iglewski
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

3.  Localised upper airway obstruction in a patient with acquired immunodeficiency syndrome.

Authors:  C L D'Arsigny; S Ford; D E O'Donnell
Journal:  Postgrad Med J       Date:  1998-10       Impact factor: 2.401

4.  Pantethine rescues phosphopantothenoylcysteine synthetase and phosphopantothenoylcysteine decarboxylase deficiency in Escherichia coli but not in Pseudomonas aeruginosa.

Authors:  Carl J Balibar; Micah F Hollis-Symynkywicz; Jianshi Tao
Journal:  J Bacteriol       Date:  2011-05-06       Impact factor: 3.490

5.  Pseudomonas aeruginosa AlgR phosphorylation modulates rhamnolipid production and motility.

Authors:  Yuta Okkotsu; Prince Tieku; Liam F Fitzsimmons; Mair E Churchill; Michael J Schurr
Journal:  J Bacteriol       Date:  2013-10-04       Impact factor: 3.490

6.  Pseudomonas aeruginosa increases formation of multidrug-tolerant persister cells in response to quorum-sensing signaling molecules.

Authors:  Nina Möker; Charles R Dean; Jianshi Tao
Journal:  J Bacteriol       Date:  2010-01-22       Impact factor: 3.490

7.  Exoenzyme S ADP-ribosylates Rab5 effector sites to uncouple intracellular trafficking.

Authors:  Nathan C Simon; Joseph T Barbieri
Journal:  Infect Immun       Date:  2013-10-07       Impact factor: 3.441

8.  Time above the MIC of Piperacillin-Tazobactam as a Predictor of Outcome in Pseudomonas aeruginosa Bacteremia.

Authors:  Elias Tannous; Shelly Lipman; Antonella Tonna; Emma Hector; Ziad Hussein; Michal Stein; Sharon Reisfeld
Journal:  Antimicrob Agents Chemother       Date:  2020-07-22       Impact factor: 5.191

9.  Modulation of host cell endocytosis by the type III cytotoxin, Pseudomonas ExoS.

Authors:  Qing Deng; Joseph T Barbieri
Journal:  Traffic       Date:  2008-08-04       Impact factor: 6.215

10.  Regulation of Rab5 function during phagocytosis of live Pseudomonas aeruginosa in macrophages.

Authors:  Sushmita Mustafi; Nathalie Rivero; Joan C Olson; Philip D Stahl; M Alejandro Barbieri
Journal:  Infect Immun       Date:  2013-04-29       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.